Aurora Cannabis and Vectura Fertin Pharma, Inc. announce commercial collaboration
Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB) and Vectura Fertin Pharma, Inc. have announced a commercial collaboration to launch a new CBD lozenge on Aurora's Canadian medical cannabis patient platform. The product, developed by Cogent International (a Vectura Fertin Pharma subsidiary), will be available to Aurora's patient base, providing valuable feedback and real-world data. This collaboration may lead to the potential commercialization of other Vectura Fertin Pharma medical cannabis products in Canada.
The initial agreement has a 24-month term, with the first CBD lozenge expected to launch later in 2024. Cogent will manufacture, package, and label the products for Aurora to distribute through its direct-to-patient e-commerce sales channel. This partnership aims to advance medical cannabis options in Canada while requiring minimal additional capital investment from Aurora.
Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB) e Vectura Fertin Pharma, Inc. hanno annunciato una collaborazione commerciale per lanciare una nuova pastiglia di CBD sulla piattaforma canadese di cannabis medica di Aurora. Il prodotto, sviluppato da Cogent International (una filiale di Vectura Fertin Pharma), sarà disponibile per i pazienti di Aurora, fornendo feedback preziosi e dati reali. Questa collaborazione potrebbe portare alla potenziale commercializzazione di altri prodotti di cannabis medica di Vectura Fertin Pharma in Canada.
L'accordo iniziale ha un termine di 24 mesi, con il lancio della prima pastiglia di CBD previsto per la fine del 2024. Cogent si occuperà della produzione, imballaggio e etichettatura dei prodotti, che Aurora distribuirà attraverso il suo canale di vendita e-commerce diretto ai pazienti. Questo partenariato mira a promuovere le opzioni di cannabis medica in Canada, richiedendo al contempo un investimento di capitale aggiuntivo minimo da parte di Aurora.
Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB) y Vectura Fertin Pharma, Inc. han anunciado una colaboración comercial para lanzar una nueva pastilla de CBD en la plataforma canadiense de cannabis medicinal de Aurora. El producto, desarrollado por Cogent International (una subsidiaria de Vectura Fertin Pharma), estará disponible para la base de pacientes de Aurora, proporcionando valiosos comentarios y datos del mundo real. Esta colaboración podría llevar a la potencial comercialización de otros productos de cannabis medicinal de Vectura Fertin Pharma en Canadá.
El acuerdo inicial tiene un plazo de 24 meses, con el lanzamiento de la primera pastilla de CBD previsto para finales de 2024. Cogent se encargará de fabricar, empaquetar y etiquetar los productos para que Aurora los distribuya a través de su canal de ventas de comercio electrónico directo al paciente. Esta asociación tiene como objetivo avanzar en las opciones de cannabis medicinal en Canadá, a la vez que requiere una inversión de capital adicional mínima de Aurora.
오로라 대마초 주식회사(Aurora Cannabis Inc.) (NASDAQ: ACB) (TSX: ACB)와 벡튜라 페르틴 제약(Vectura Fertin Pharma, Inc.)이 오로라의 캐나다 의료 대마초 환자 플랫폼에서 새로운 CBD 로젠지를 출시하기 위한 상업적 협력을 발표했습니다. 이 제품은 벡튜라 페르틴 제약의 자회사인 코젠트 인터내셔널(Cogent International)이 개발했으며, 오로라의 환자 기반에게 제공되어 귀중한 피드백과 실제 데이터 수집이 가능해집니다. 이 협력은 캐나다에서 기타 벡튜라 페르틴 제약 의료 대마초 제품의 잠재적 상업화로 이어질 수 있습니다.
초기 계약은 24개월 기간을 가지며, 첫 번째 CBD 로젠지는 2024년 말에 출시될 예정입니다. 코젠트는 오로라가 환자 직접 전자상거래 판매 채널을 통해 유통할 제품을 제조, 포장 및 라벨링할 것입니다. 이 파트너십은 오로라 측에서 최소한의 추가 자본 투자를 요구하면서 캐나다 내 의료 대마초 옵션을 발전시키는 것을 목표로 하고 있습니다.
Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB) et Vectura Fertin Pharma, Inc. ont annoncé une collaboration commerciale pour lancer un nouveau lozenge de CBD sur la plateforme de cannabis médical canadien d'Aurora. Le produit, développé par Cogent International (une filiale de Vectura Fertin Pharma), sera disponible pour la base de patients d'Aurora, offrant des retours précieux et des données du monde réel. Cette collaboration pourrait conduire à la commercialisation potentielle d'autres produits médicaux de cannabis de Vectura Fertin Pharma au Canada.
Le contrat initial a une durée de 24 mois, avec le lancement de la première pastille de CBD prévu pour la fin de l'année 2024. Cogent sera chargé de fabriquer, d'emballer et d'étiqueter les produits pour qu'Aurora les distribue via son canal de vente en ligne direct aux patients. Ce partenariat vise à faire progresser les options de cannabis médical au Canada tout en exigeant un investissement en capital supplémentaire minimal de la part d'Aurora.
Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB) und Vectura Fertin Pharma, Inc. haben eine kommerziellen Zusammenarbeit bekannt gegeben, um ein neues CBD-Lutschtablette auf Auroras kanadischer Plattform für medizinisches Cannabis zu lancieren. Das Produkt, das von Cogent International (einer Tochtergesellschaft von Vectura Fertin Pharma) entwickelt wurde, wird der Patientengruppe von Aurora zur Verfügung stehen und wertvolles Feedback sowie reale Daten liefern. Diese Zusammenarbeit könnte zur potenziellen Kommerzialisierung weiterer medizinischer Cannabisprodukte von Vectura Fertin Pharma in Kanada führen.
Der anfängliche Vertrag hat eine Laufzeit von 24 Monaten, wobei die erste CBD-Lutschtablette für später im Jahr 2024 geplant ist. Cogent wird die Produkte herstellen, verpacken und kennzeichnen, damit Aurora diese über ihren Direktvertriebskanal für Patienten vertreiben kann. Diese Partnerschaft zielt darauf ab, die Optionen für medizinisches Cannabis in Kanada voranzubringen und gleichzeitig einen minimalen zusätzlichen Kapitalaufwand für Aurora zu erfordern.
- Expansion of Aurora's product portfolio with a new CBD lozenge
- Access to Vectura Fertin Pharma's innovative medical cannabis products
- Potential for future commercialization of additional medical cannabis products
- Minimal capital investment required from Aurora for product launch
- Opportunity to gather valuable patient feedback and real-world data
- None.
Insights
This collaboration between Aurora Cannabis and Vectura Fertin Pharma marks a significant step in the evolution of medical cannabis products. The introduction of a CBD lozenge through Aurora's established patient platform in Canada presents an intriguing opportunity for both companies.
From a market perspective, this move could potentially expand Aurora's product portfolio and strengthen its position in the medical cannabis sector. The 24-month initial term of the agreement provides a solid timeframe for product launch and data collection, which is important for validating the product's efficacy and market potential.
The collaboration's focus on real-world patient data is particularly noteworthy. This approach aligns with the growing trend in the pharmaceutical industry of utilizing patient-centric data to inform product development and improve treatment outcomes. It's a strategic move that could provide valuable insights for future product iterations and potentially support regulatory submissions.
However, investors should note that the success of this venture hinges on several factors:
- Regulatory approval and compliance with Canadian cannabis regulations
- Patient acceptance and adoption of the new CBD lozenge format
- The ability to effectively collect and analyze real-world data
- Potential competition from other CBD-based products in the market
While the collaboration shows promise, it's important to remember that the medical cannabis market is still evolving and regulatory landscapes can shift rapidly. The targeted launch later in 2024 gives both companies time to navigate these challenges, but also leaves room for market conditions to change.
Overall, this partnership represents a calculated move by Aurora to diversify its product offerings and potentially tap into Vectura Fertin Pharma's expertise in pharmaceutical-grade products. If successful, it could pave the way for further innovations in medical cannabis delivery methods and strengthen Aurora's competitive position in the global medical cannabis market.
The collaboration between Aurora Cannabis and Vectura Fertin Pharma to launch a CBD lozenge is an intriguing development in the medical cannabis space. This partnership combines Aurora's established presence in the Canadian medical cannabis market with Vectura Fertin Pharma's expertise in pharmaceutical product development.
The choice of a lozenge as the delivery method is particularly interesting. Lozenges offer several potential advantages over traditional cannabis consumption methods:
- Precise dosing: Each lozenge can contain a standardized amount of CBD
- Discreet consumption: Lozenges are less conspicuous than smoking or vaping
- Potentially faster onset: Sublingual absorption could lead to quicker effects compared to oral ingestion
- Extended release: Depending on the formulation, lozenges could provide a sustained release of CBD
The focus on gathering real-world patient data is a important aspect of this collaboration. This approach aligns with the growing emphasis on evidence-based medicine and could provide valuable insights into the efficacy and patient experience of CBD lozenges. Such data could be instrumental in refining the product and potentially supporting future regulatory submissions.
However, it's important to note that while CBD has shown promise in various therapeutic applications, more research is needed to fully understand its effects and optimal dosing. The real-world data collected through this collaboration could contribute significantly to this body of knowledge.
From a research perspective, this collaboration opens up exciting possibilities for studying the pharmacokinetics and pharmacodynamics of CBD delivered via lozenges. It could potentially lead to new insights into the bioavailability and efficacy of CBD when administered through this route.
Overall, this partnership represents a step towards more standardized, pharmaceutical-grade cannabis products. If successful, it could pave the way for similar innovations in medical cannabis delivery methods and potentially increase the acceptance of cannabis-based medicines among healthcare professionals and patients alike.
Collaboration will initially see launch of a new CBD lozenge from Cogent International, a Vectura Fertin Pharma subsidiary, on Aurora's Canadian medical cannabis patient platform
Following successful launch of CBD lozenge, the collaboration will explore the potential to launch Vectura Fertin Pharma's future medical cannabis portfolio in
"We are excited about this commercial collaboration that will allow Aurora to leverage its industry-leading patient platform in
Michael Kunst, CEO for Vectura Fertin Pharma, said: "At Vectura Fertin Pharma, we are committed to building a pipeline of innovation, based on scientific rigor, to improve unmet medical and health needs. We are delighted to be working with the Aurora team who share our high standards for safety and quality, and our strong focus on improving people's lives. Through this strategic collaboration, the Aurora platform will enable us to bring our new CBD lozenge, as prescribed by a healthcare professional, to the largest patient base in
Select Agreement Details
The agreement between Aurora and Cogent is expected to have an initial term of 24 months, with a target of launching CBD containing products on Aurora's Canadian medical cannabis marketplace, starting with a CBD lozenge. The products will be manufactured, packaged and labelled by Cogent for sale and distribution by Aurora through its leading direct-to-patient e-commerce sales channel, requiring minimal additional capital investment by Aurora. The expected launch of the first SKU in market is targeted for later in 2024.
About Aurora Cannabis
Aurora is opening the world to cannabis, serving both the medical and consumer markets across Canada, Europe, Australia and South America. Headquartered in Edmonton,
Aurora's common shares trade on the NASDAQ and TSX under the symbol "ACB".
About Vectura Fertin Pharma
At Vectura Fertin Pharma, we are developing and commercializing a proprietary pipeline of differentiated products and brands in wellness and healthcare that address unmet patient and consumer needs. We have unique R&D capabilities in inhaled and oral technology, which we are applying across four key areas: Cannabinoids, Inhaled Therapeutics, Nicotine Replacement Therapy and Consumer Health. Underpinned by scientific rigor, and patient and consumer insights, we are passionate about finding new and better ways to help people take care of their health and wellbeing. Vectura Fertin Pharma was formed in March 2022 following the acquisition of Fertin Pharma, Vectura Group PLC and OtiTopic by Philip Morris International. For more information, visit www.vecturafertinpharma.com or LinkedIn.
Forward Looking Information
This news release includes statements containing certain "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"). Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements made in this news release include statements regarding the Company's commercialization collaboration with Cogent, which include, but are not limited to, those statements under the heading "Select Agreement Details", statements related to the launch of Cogent's newly-developed CBD lozenge on Aurora's Canadian medical cannabis patient platform, the potential to launch Vectura Fertin Pharma's future medical cannabis portfolio, the Company's ability to support advancements in medical cannabis and to provide its patients with access to new products, the ability for Vectura Fertin Pharma to study the efficacy and other patient responses to the product while building real-world patient data for future analysis, and increased interest in the possibilities of medical cannabis.
These forward-looking statements are only predictions. Forward looking information or statements contained in this news release have been developed based on assumptions management considers to be reasonable. Material factors or assumptions involved in developing forward-looking statements include, without limitation, publicly available information from governmental sources as well as from market research and industry analysis and on assumptions based on data and knowledge of this industry which the Company believes to be reasonable. Forward-looking statements are subject to a variety of risks, uncertainties and other factors that management believes to be relevant and reasonable in the circumstances could cause actual events, results, level of activity, performance, prospects, opportunities or achievements to differ materially from those projected in the forward-looking statements. These risks include, but are not limited to, the ability to retain key personnel, the ability to continue investing in infrastructure to support growth, the ability to obtain financing on acceptable terms, the continued quality of our products, customer experience and retention, the development of third party government and nongovernment consumer sales channels, management's estimates of consumer demand in
View original content to download multimedia:https://www.prnewswire.com/news-releases/aurora-cannabis-and-vectura-fertin-pharma-inc-announce-commercial-collaboration-302212087.html
SOURCE Aurora Cannabis Inc.
FAQ
What is the new product Aurora Cannabis (ACB) is launching through this collaboration?
When is Aurora Cannabis (ACB) expected to launch the new CBD lozenge?
What is the duration of the agreement between Aurora Cannabis (ACB) and Cogent International?
How will Aurora Cannabis (ACB) distribute the new CBD products?
